RESEARCH NOTES
PRESSURE BIOSCIENCES - PBIO OTCBB - OUR TARGET $1.25
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell"In a research lab, one of the most critical parts of scientific research is what we call sample preparation. It is absolutely critical that you are as good as you can be when you’re preparing the sample for analysis, Pressure Biosciences Inc CEO Richard T. Schumacher told Benzinga in a recent interview."Schumacher went on to explain that in a single cell, there could be between 5,000 and 10,000 different proteins and as many as 1,000 different lipids, plus DNA and RNA. “So, as a scientist, you want to break open the cell to free as many of these proteins and lipids and the DNA and RNA, so that you can study them,” he added. “It may be one small change on one protein that makes the difference between life and death, between ability to fight off a disease or not, the ability to develop a drug or not develop a drug.” “So, it’s crucial that when you break open the cell you do it in a very efficacious, a very high quality manner, so that you get as many of these proteins as possible and in as good a shape as possible,” Schumacher explicated. Breaking A Paradigm“Pressure Biosciences is a life science tools company. We make instruments and associated consumables that are sold into the scientific research community worldwide,” the chief executive told Benzinga. “We have five instruments (three of them are on the market, and the two remaining ones are close) and about ten different consumable products that are used by researchers in their studies of human, animal and plant disease,” he elaborated. “We’ve had over 100 scientific publications from independent investigators, some of them being key opinion leaders that are talking about our system and how it worked in their scientific research [...] We are breaking a paradigm that’s existed for many, many decades. For decades, scientists have broken cells to study things inside them without much care about how they break this cells. They use mechanical means; it’s like opening up a walnut with a sledgehammer.” “We’ve developed a method that is far more controllable,” he supplemented. “Every cell is different, and you don’t want to put too much pressure or too little pressure. What we do is use pulses of pressure [...]so every molecule in the cell will feel the pressure that you exert.” The Client SlateWhen asked who had acquired the more than 250 Pressure Biosciences devices out there, Schumacher said the company goes after key opinion leaders around the world — some of the top protein, lipids and DNA experts. The existing customers list includes:
MORE ON PBIO UPLISTING TO NASDAQ Benzinga had the chance to chat with the company’s CEO Richard T. Schumacher, who shared some insights into the stock, the company and its growth initiatives. A Beaten Down StockQuestioned about Pressure Biosciences’ stock’s recent underperformance, the exec voiced, “I think the stock is significantly undervalued. When the stock was in the $0.50 per share range just three months ago, we thought the same.” “The stock is at a level now where it was six months ago, when we had $3 million of toxic debt, no next-generation instruments, no line of credit, and no deal with a leading mass spectrometry company in the world,” he said, referencing some of the milestones described below. Recent MilestonesThe chief executive went on to point out a few milestones investors should take into account when considering an investment. These include:
This makes the company “financially secure” for the first time in several quarters, Schumacher assured. “What this means to us is that we can begin to focus on the area that we think is most important: sales and marketing.” So, what the company is doing is assembling a small sales team. In addition, Pressure Biosciences closed a co-marketing agreement with instrumentation provider SCIEX — a wholly owned subsidiary of the Danaher Corporation HR 0.19%. “We now work hand in glove with SCIEX, so we don’t need sales people to support that,” he expounded. Companies like Thermo Fisher Scientific Inc. Agilent Technologies Inc Bruker Corporation and Waters Corporation all make mass spectrometers, Schumacher went on to explain. “Our system sits in front of a mass spectrometer and –we think- makes the mass spectrometer results better,” he assured. “So, now that we’ve received equity and debt financing [...] we are going to build a sales force focused on going out and getting customers, primarily those who have a mass spectrometer, because of the 100+ papers that have been published, most of them –although not all, deal with using our system in front of a mass spectrometer and getting better results. So that’s our low hanging fruit.” Looking AheadWhen asked about a possible uplisting of the stock to the Nasdaq exchange next year, Schumacher responded, “we understand, as a company, that it’s important to get on a national exchange, and we are looking into the possibility of an uplist. It is a goal of ours to uplist the company in the near future.” Richard T. Schumacher owns about 10 percent of the company’s shares outstanding, as disclosed during the interview.
Forward Looking & Disclaimer / Privacy
About TopStockReporter.com :
|